<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02831218</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2016-13</org_study_id>
    <nct_id>NCT02831218</nct_id>
  </id_info>
  <brief_title>Quantitative Coronary Angiography Versus Imaging GUIDancE for Bioresorbable Vascular Scaffold Implantation</brief_title>
  <acronym>GUIDE-BVS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare clinical outcomes between QCA(quantitative coronary
      angiography)-guided and imaging-guided strategy in patients with native coronary artery
      disease undergoing Bioresorbable Vascular Scaffold implantation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was merged into HOWTO-BRS study.
  </why_stopped>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>1 year</time_frame>
    <description>the cumulative incidence of cardiac death, target vessel myocardial infarction or ischemia-driven target lesion revascularization at 12 months after the index procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>1 day</time_frame>
    <description>Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>24 hours</time_frame>
    <description>Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel myocardial infarction or repeat target lesion revascularization during the hospital stay (24 hour after an index procedure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>1 year and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scaffold thrombosis</measure>
    <time_frame>1 year and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>1 year and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>1 year and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>1 year and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>1 year and 5 years</time_frame>
    <description>cardiac death, target vessel myocardial infarction or ischemia-driven target lesion failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of net clinical events</measure>
    <time_frame>5 years</time_frame>
    <description>defined as composite event of cardiovascular death, myocardial infarction, stroke, clinically relevant bleeding</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Percutaneous Transluminal Coronary Angioplasty</condition>
  <arm_group>
    <arm_group_label>QCA and Aspirin alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QCA and Clopidogrel alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Imaging guided and Aspirin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Imaging guided and Clopidogrel alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>QCA and Aspirin</intervention_name>
    <description>QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.</description>
    <arm_group_label>QCA and Aspirin alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>QCA and Clopidogrel</intervention_name>
    <description>QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.</description>
    <arm_group_label>QCA and Clopidogrel alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Imaging guided and Aspirin</intervention_name>
    <description>BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.</description>
    <arm_group_label>Imaging guided and Aspirin alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Imaging guided and Clopidogrel</intervention_name>
    <description>BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.</description>
    <arm_group_label>Imaging guided and Clopidogrel alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women at least 18 years of age

          -  Typical chest pain or objective evidence of myocardial ischemia suitable for elective
             percutaneous coronary intervention

          -  Native coronary artery lesions with lesion length ≤ 50mm and reference vessel diameter
             of 2.3 - 3.75mm by QCA(quantitative coronary angiography) assessment

          -  The patient or guardian agrees to the study protocol and the schedule of clinical
             follow-up, and provides informed, written consent, as approved by the appropriate
             Institutional Review Board/Ethical Committee of the respective clinical site.

        Exclusion Criteria:

          -  Angiographic exclusion criteria: any of the followings

               1. Small vessel: mean reference size &lt; 2.3 mm by QCA(quantitative coronary
                  angiography)

               2. True bifurcation lesion with a large side branch (reference vessel diameter &gt;
                  2.3mm) requiring a complex two-stent approach

               3. Left main lesions

               4. Ostial lesions within 3mm of the origin: right coronary artery, left anterior
                  descending artery, or left circumflex artery

               5. Impaired delivery of the Absorb BVS is expected:

          -  Extreme angulation (≥90°) proximal to or within the target lesion.

          -  Excessive tortuosity (≥two 45° angles) proximal to or within the target lesion.

          -  Moderate or heavy calcification proximal to or within the target lesion. 6. In-stent
             restenotic lesions

          -  ST-elevation myocardial infarction undergoing primary percutaneous coronary
             intervention (with 12- 24 hour after symptoms onset)

          -  Prior percutaneous coronary intervention within the target vessel during the last 12
             months.

          -  Prior percutaneous coronary intervention within the non-target vessel or any
             peripheral intervention is acceptable if performed anytime &gt;30 days before the index
             procedure, or between 24 hours and 30 days before the index procedure if successful
             and uncomplicated.

          -  Left ventricular ejection fraction (LVEF) &lt; 30%

          -  Hypersensitivity or contraindication to device material and its degradants
             (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and cobalt,
             chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be
             adequately pre-medicated.

          -  Persistent thrombocytopenia (platelet count &lt;100,000/µl)

          -  Any history of hemorrhagic stroke or intracranial hemorrhage, transient ischemic
             attack (TIA) or ischemic stroke within the past 6 months

          -  A known intolerance to a study drug (aspirin, clopidogrel or ticagrelor)

          -  Patients requiring long-term oral anticoagulants or cilostazol

          -  Any surgery requiring general anesthesia or discontinuation of aspirin and/or an ADP
             antagonist is planned within 12 months after the procedure.

          -  A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in
             the past 3 years or current treatment for the active cancer.

          -  Any clinically significant abnormality identified at the screening visit, physical
             examination, laboratory tests, or electrocardiogram which, in the judgment of the
             Investigator, would preclude safe completion of the study.

          -  Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation
             (ALT or AST &gt; 3 times upper limit of normal).

          -  Life expectancy &lt; 5 years for any non-cardiac or cardiac causes

          -  Unwillingness or inability to comply with the procedures described in this protocol.

          -  Patient's pregnant or breast-feeding or child-bearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>professor of medicine</investigator_title>
  </responsible_party>
  <keyword>bioresorbable vascular scaffold</keyword>
  <keyword>coronary artery disease</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is not a publicly funded trial.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

